Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that it has secured a bridge financing through the issuance of convertible bonds to European investors, including Vester Finance, a Company's shareholder and long-term financing partner.
This financing immediately extends Mauna Kea Technologies' financial visibility through November 2025, beyond the timeframe of the ongoing safeguard procedure. It provides the Company with the flexibility needed to complete its financial restructuring and finalize the presentation of its safeguard plan. Mauna Kea Technologies is also working on structuring a bridge financing intended to ensure business continuity during the observation period.
In parallel, the Company is actively structuring a long-term financing plan with strategic investors and family offices to sustainably support Mauna Kea Technologies' operational development.
Sacha Loiseau, Ph.D., Chief Executive Officer of Mauna Kea Technologies, stated: "I would like to sincerely thank the investors for their valuable support, as well as Vester Finance, a long-standing partner of the Company, for reiterating its support and confidence. With a deliberately targeted amount, this bridge financing is perfectly suited to our current needs, extending our cash runway for the time required to finalize our recovery plan with all stakeholders, while preserving maximum options for the future."
Key Terms of the Convertible Bond Issuance
The issuance of convertible bonds was carried out based on the delegation granted by the Company's shareholders during the General Meeting held on June 5, 2025, under the 12 th resolution 1. This issue was carried out on the basis of Article L. 225-138 of the French Commercial Code, with the removal of preferential subscription rights in favor of a category of investors meeting the characteristics determined by the General Meeting 2.
The convertible bonds, with a nominal unit value of €10 and a total nominal value of €1,956,510 were subscribed at 92% of their nominal value, for a total subscription price of €1,799,989.20 paid in full on the day of subscription. The bonds will bear no interest.
The conversion price will be determined based on the stock market price 3 at the time of conversion, in accordance with pricing rules and the ceiling set by the shareholders' meeting.
The proceeds will fund the Company's operating and investment needs (excluding any repayment of existing financial debt), extending its cash visibility until November 2025. Unconverted bonds will be redeemed at maturity at 100% of their nominal value 24 months after issuance. Bonds may be converted at any time from the issue date until maturity. This transaction was advised by Vester Finance, which is also a subscriber to OC0727.
For illustrative purposes, if all convertible bonds were converted based on the Mauna Kea stock closing price on July 9, 2025, a shareholder holding 1% of the capital prior to the issuance and conversion would hold 0.82% of the capital on a non-diluted basis and 0.69% on a fully diluted basis. The new shares issued from conversion will be fully fungible with existing ordinary shares and will carry the same rights.
Risk Factors
Risk factors affecting the Company are detailed in Chapter 2 of the 2024 Annual Report, published on April 30, 2025, and available on the Mauna Kea Technologies Company's website (https://www.maunakeatech.com/fr/finances/).
As previously stated by the Company in its press releases regarding the ongoing safeguard procedure, Mauna Kea Technologies' financial situation remains fragile. The bond financing described above is a first step but does not in itself guarantee business continuity. The Company continues to actively seek additional funding and is negotiating its financial liabilities. Updates will be provided regularly to the market regarding the safeguard procedure and the financial status of Mauna Kea.
Since the bond conversion price is linked to the Company's share price, the exact number of shares to be issued upon conversion cannot be determined at the time of issuance, and such conversion may significantly dilute existing shareholders.
A sensitivity table (provided for illustrative purposes only) outlines potential dilution scenarios based on share price changes.
* Closing price on July 9, 2025, i.e. €0.12
Prospectus – Admission to trading
The bonds will not be subject to any application for admission to trading on Euronext Growth. This issue does not give rise to the preparation of a prospectus subject to the approval of the Autorité des marchés financiers (AMF).
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
________________________________
1 Delegation of authority, with removal of the preferential subscription right reserved for members of a category of persons, to decide on the issuance of common shares, financial securities, or any securities that may give rise to one or more increases in share capital for a maximum nominal amount of €4,212,127.
2 Namely, under the terms of the 12 resolution of the General Meeting: 'any natural or legal person, including companies, trusts, investment funds, or other investment vehicles of any kind, whether governed by French or foreign law, that regularly invests in the pharmaceutical or medical technology sector.'
3 At least equal to the lower of (i) €0.17 and (ii) 94% of the lowest of the volume-weighted average daily prices over a 10-day period preceding each conversion request.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Sanuwave Health reports Q2 EPS 1c vs $1.77 last year
Reports Q2 revenue $10.2M vs $7.2M last year. 'We're pleased to have put up strong results for Q2 and to have achieved 51% revenue growth in the first six months of 2025 vs the same period in 2024 ,' said Morgan Frank, CEO. 'We sold 214 UltraMIST systems in the first six months of this year, more than we did in the full year of 2023 and an increase of 86% versus same period in 2024. Q1 and Q2 have been spent building and reshaping our sales and commercial operations teams, and as of mid July, the Company achieved full national sales coverage for the first time in my tenure as CEO. If Q1 and Q2 were the quarters of 'max disruption' Q3 is expected to be the quarter of 'max construction' as the Company builds up momentum around our new sales and marketing practices (including the launch of our first concerted marketing program) with an aim to set us up for breakout performance in Q4 2025 and 2026. The energy at our sales and commercial operations national meeting a couple of weeks ago was palpable. I think we're all looking forward to seeing what Sanuwave can become as it starts firing on all cylinders.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
2 hours ago
- Yahoo
McCormick (MKC) Gets Price Target Cut as Stifel Flags Sector-Wide Caution
McCormick & Company Inc. (NYSE:MKC) is one of the best defensive stocks to invest in according to analysts. In its Q2 2025 results report at the end of June, the company highlighted headwinds from tariff costs over FY 2025, which it plans to offset through adjustments in sourcing of materials, pricing, and cost discipline. However, pricing seems to be slightly less elastic for the company, and most of the revenue growth appears to be coming from higher volumes, as pricing has declined for the last three quarters, while it contributed only 0.3% towards the organic sales growth of 1.6% in Q2. McCormick's share price has already lost around 8% YTD, and the market appears cautious on the consumption trends. In a note dated July 29, Stifel Nicolaus analyst Matthew Smith revised his outlook on the company and lowered the price target from $82 to $76 while maintaining a Hold rating. Smith expressed a cautious stance ahead of the second-quarter earnings season, particularly for food sector stocks under his coverage. The analyst pointed to ongoing softness in consumer demand that persisted through the second quarter, contributing to a more conservative view on the group's performance. For 2025, Stifel projects only about 1% organic sales growth across its food and beverage coverage universe, alongside an average EPS decline of 15%. Given these subdued expectations, the analyst advised investors to take a selective approach when considering exposure to the food sector. McCormick & Company Inc. (NYSE:MKC) manufactures and markets spices, seasoning mixes, condiments, flavour solutions, and other products to the food industry. While we acknowledge the potential of MKC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
The Hill
2 hours ago
- The Hill
Vance: ‘We're done with the funding of the Ukraine war business'
Vice President Vance on Sunday said he wants peace and to stop funding the Ukraine war, ahead of a Friday meeting in Alaska between President Trump and Russian President Vladimir Putin to discuss a ceasefire deal. 'We're done with the funding of the Ukraine war business. We want to bring about a peaceful settlement to this thing,' Vance told Fox News's Maria Bartiromo on 'Sunday Morning Futures.' In Alaska, the Trump administration hopes for a breakthrough in peace negotiations with Moscow and a discussion around territorial acquisitions. Earlier this week, the Kremlin shared a ceasefire deal with the Trump administration, asking for control of Eastern Ukraine in exchange for a halt in hostilities. Ukrainian President Volodymyr Zelensky adamantly opposed the deal, stating on X, 'Ukraine is ready for real decisions that can bring peace. Any decisions that are against us, any decisions that are without Ukraine, are at the same time decisions against peace.' Zelensky was not invited to the summit, but the White House and the NATO Ambassador, Matthew Whitaker, have said that it's a possibility and Trump is open to a trilateral summit. This uneven deal led to an intense response from European leaders, who said they would support Trump's effort diplomatically and through economic and military means but that a resolution 'must protect Ukraine's and Europe's vital security interests.' Trump vowed to end the conflict in 24 hours during his presidential campaign, but negotiations are harder than anticipated and the 3-year-long conflict is costly for both America and Europe. 'Americans, I think, are sick of continuing to send their money, their tax dollars of this particular conflict but if the Europeans want to step up and actually buy the weapons from American producers were okay with that but were not gonna fund it ourselves anymore,' Vance continued. This is not the first time the vice president has asked European leaders to take on a bigger role. However, in June, Trump secured a historic deal for NATO allies to spend five percent of their GDP on defense. In July, the president made another deal with NATO for the U.S. to send lethal weapons to Ukraine that were purchased by other NATO countries. These two steps significantly grew Europe's economic involvement in the Russia-Ukraine war. Vance went to England on Saturday to discuss Trump's efforts towards peace. 'What we said to Europeans is simply, first of all, this is in your neck of the woods, this is in your backdoor, you guys have got to step up and take a bigger role in this thing, and if you care so much about this conflict you should be willing to play a more direct and a more substantial way in funding this war yourself,' Vance said on Fox News.
